US President Donald Trump’s administration has selected five companies, including Moderna Inc, AstraZeneca PLC and Pfizer Inc, as the most likely candidates to produce a COVID-19 vaccine, the New York Times reported on Wednesday, citing senior officials.
The other companies are Johnson & Johnson (J&J) and Merck & Co Inc, according to the paper.
The selected companies would have access to additional government funds, help in running clinical trials, and financial and logistical support, the New York Times reported.
There is no approved vaccine for COVID-19, the respiratory disease caused by the novel coronavirus.
The report did not mention potential vaccines from French drugmaker Sanofi SA, Novavax Inc and Inovio Pharmaceuticals Inc — among the more than 100 vaccines in development globally.
The announcement of the decision would be made at the White House in the next few weeks, the report said.
The White House did not immediately respond to a request for comment.
“We cannot comment on information that is market-moving,” a US Department of Health and Human Services official said.
The companies on the list are the farthest along in developing a vaccine and have significant manufacturing capacity.
The US is planning massive clinical trials involving 100,000 to 150,000 volunteers in total, with the goal of delivering an effective vaccine by the end of this year.
To make that deadline, the government aims to start mid-stage testing next month.
The first two vaccines to start mid-stage trials would likely be from Moderna and the AstraZeneca with Oxford University combination, US National Institutes of Health Director Francis Collins said in an interview last month.
He said he expected vaccine candidates from J&J and Merck to eventually join the trial effort.
US National Institute of Allergy and Infectious Diseases Director Anthony Fauci on Tuesday said that he hoped to have “a couple hundred million doses” by the start of next year, CNN reported.
Separately, Germany and three other EU states are forging a new alliance aimed at securing access to coronavirus vaccines, once developed, and making sure they are distributed fairly around the world, business daily Handelsblatt reported.
Handelsblatt quoted German Minister of Health Jens Spahn and his colleagues from France, Italy and the Netherlands as writing in a letter to the EU Commission that it had seen access to vaccines as “one of the most urgent issues that the European Union has to address at present.”
Therefore, a core group of member states had joined up to “achieve the fastest and best possible outcome in negotiations with key players in the pharmaceutical industry.”
The four, acting on Berlin’s initiative, want to prevent the EU from losing out to the US and China in the race for a COVID-19 vaccine, the paper reported.
Efforts by Trump to gain first access to vaccine candidates in return for billions of US dollars invested in pharmaceutical companies are viewed with suspicion in Europe, Handelsblatt added.
The US has secured almost a third of the first 1 billion doses planned for AstraZeneca’s experimental COVID-19 vaccine by pledging up to US$1.2 billion, as world powers scramble for medicines to get their economies back to work.
Handelsblatt cited government sources as saying that Germany, France, Italy and the Netherlands were talking to several pharmaceutical companies, including AstraZeneca, about government research funds and purchase guarantees.
Europe must build up a “market power” in order to survive in the struggle for vaccines, Handelsblatt cited government sources in Berlin as saying.
The four were also talking to Britain, Norway, Singapore and Japan about possible cooperation.
ISSUES: Gogoro has been struggling with ballooning losses and was recently embroiled in alleged subsidy fraud, using Chinese-made components instead of locally made parts Gogoro Inc (睿能創意), the nation’s biggest electric scooter maker, yesterday said that its chairman and CEO Horace Luke (陸學森) has resigned amid chronic losses and probes into the company’s alleged involvement in subsidy fraud. The board of directors nominated Reuntex Group (潤泰集團) general counsel Tamon Tseng (曾夢達) as the company’s new chairman, Gogoro said in a statement. Ruentex is Gogoro’s biggest stakeholder. Gogoro Taiwan general manager Henry Chiang (姜家煒) is to serve as acting CEO during the interim period, the statement said. Luke’s departure came as a bombshell yesterday. As a company founder, he has played a key role in pushing for the
China has claimed a breakthrough in developing homegrown chipmaking equipment, an important step in overcoming US sanctions designed to thwart Beijing’s semiconductor goals. State-linked organizations are advised to use a new laser-based immersion lithography machine with a resolution of 65 nanometers or better, the Chinese Ministry of Industry and Information Technology (MIIT) said in an announcement this month. Although the note does not specify the supplier, the spec marks a significant step up from the previous most advanced indigenous equipment — developed by Shanghai Micro Electronics Equipment Group Co (SMEE, 上海微電子) — which stood at about 90 nanometers. MIIT’s claimed advances last
CROSS-STRAIT TENSIONS: The US company could switch orders from TSMC to alternative suppliers, but that would lower chip quality, CEO Jensen Huang said Nvidia Corp CEO Jensen Huang (黃仁勳), whose products have become the hottest commodity in the technology world, on Wednesday said that the scramble for a limited amount of supply has frustrated some customers and raised tensions. “The demand on it is so great, and everyone wants to be first and everyone wants to be most,” he told the audience at a Goldman Sachs Group Inc technology conference in San Francisco. “We probably have more emotional customers today. Deservedly so. It’s tense. We’re trying to do the best we can.” Huang’s company is experiencing strong demand for its latest generation of chips, called
GLOBAL ECONOMY: Policymakers have a choice of a small 25 basis-point cut or a bold cut of 50 basis points, which would help the labor market, but might reignite inflation The US Federal Reserve is gearing up to announce its first interest rate cut in more than four years on Wednesday, with policymakers expected to debate how big a move to make less than two months before the US presidential election. Senior officials at the US central bank including Fed Chairman Jerome Powell have in recent weeks indicated that a rate cut is coming this month, as inflation eases toward the bank’s long-term target of two percent, and the labor market continues to cool. The Fed, which has a dual mandate from the US Congress to act independently to ensure